Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

More women vs. men veterans with COPD received spirometry and tobacco cessation interventions, but more men received correct ...

Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

Basel: Roche has announced topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) ...

Roche announces positive results from pivotal phase IIb ALIENTO & phase III ARNASA trials of astegolimab to treat COPD: Basel Tuesday, July 22, 2025, 13:00 Hrs [IST] Roche announc ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase ...

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in ...

Digital inhalers can detect significant changes in physiologic and inhaler use metrics in the 14 days before COPD exacerbations.

Cambridge-based start-up rolls out industry-first inhaler for delivering large amounts of drug in a single inhalation, enabling next-gen inhaled biologics for novel therapiesCAMBRIDGE, 24 June 2025: ...

Between 14 days and 1 day out from an acute exacerbation of COPD, a digital inhaler measured significant drops in inhalation volume, inhalation duration and time to peak, according to study ...

Avalyn Pharma has drawn in another fundraising round, this time a $100 million oversubscribed series D to continue developing ...

Breztri can cost around $400 without insurance. Medicare drug plans may cover inhalers for COPD, including drugs like Breztri, but specific coverage and cost depend on the exact plan.